Equity Overview
Price & Market Data
Price: $4.33
Daily Change: -$0.09 / 2.08%
Range: $4.29 - $4.41
Market Cap: $696,674,240
Volume: 1,777,101
Performance Metrics
1 Week: -5.02%
1 Month: -6.25%
3 Months: -9.75%
6 Months: 21.51%
1 Year: 89.13%
YTD: 28.32%
Company Details
Employees: 394
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.